CyTOF-Enabled Analysis Identifies Class-Switched B Cells as the Main Lymphocyte Subset Associated With Disease Relapse in Children With Idiopathic Nephrotic Syndrome.
Adolescent
Adult
Antibodies, Monoclonal, Humanized
/ pharmacology
Antigens, CD20
/ immunology
B-Lymphocyte Subsets
/ immunology
Child
Child, Preschool
Female
Humans
Immunoglobulin Class Switching
Immunologic Factors
/ pharmacology
Lymphocyte Count
Lymphocyte Depletion
Male
Mass Spectrometry
Nephrotic Syndrome
/ drug therapy
Recurrence
Rituximab
/ pharmacology
T-Lymphocyte Subsets
/ immunology
Young Adult
B cell
T cell
immune phenotype
nephrotic syndrome
predictor
relapse
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
16
06
2021
accepted:
01
09
2021
entrez:
8
10
2021
pubmed:
9
10
2021
medline:
27
11
2021
Statut:
epublish
Résumé
B cell depleting therapies permit immunosuppressive drug withdrawal and maintain remission in patients with frequently relapsing nephrotic syndrome (FRNS) or steroid-dependent nephrotic syndrome (SDNS), but lack of biomarkers for treatment failure. Post-depletion immune cell reconstitution may identify relapsing patients, but previous characterizations suffered from methodological limitations of flow cytometry. Time-of-flight mass cytometry (CyTOF) is a comprehensive analytic modality that simultaneously quantifies over 40 cellular markers. Herein, we report CyTOF-enabled immune cell comparisons over a 12-month period from 30 children with SDNS receiving B cell depleting therapy who either relapsed (n = 17) or remained stable (n = 13). Anti-CD20 treatment depleted all B cells subsets and CD20 depleting agent choice (rituximab
Identifiants
pubmed: 34621271
doi: 10.3389/fimmu.2021.726428
pmc: PMC8490633
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Antigens, CD20
0
Immunologic Factors
0
Rituximab
4F4X42SYQ6
ofatumumab
M95KG522R0
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
726428Informations de copyright
Copyright © 2021 Fribourg, Cioni, Ghiggeri, Cantarelli, Leventhal, Budge, Bin, Riella, Colucci, Vivarelli, Angeletti, Perin and Cravedi.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Nat Immunol. 2011 Jun;12(6):492-9
pubmed: 21739672
Mol Immunol. 2009 Jul;46(11-12):2419-23
pubmed: 19427037
Pediatr Nephrol. 2013 Mar;28(3):415-26
pubmed: 23052651
J Am Soc Nephrol. 2013 Jan;24(1):149-59
pubmed: 23274956
Cytometry B Clin Cytom. 2018 Sep;94(5):588-601
pubmed: 28865188
Immunology. 2006 Apr;117(4):548-57
pubmed: 16556269
Kidney Int. 2013 Nov;84(5):1025-33
pubmed: 23739238
Blood. 2003 Sep 15;102(6):2146-55
pubmed: 12763926
Cell Mol Immunol. 2013 Mar;10(2):122-32
pubmed: 23292280
J Am Soc Nephrol. 2016 Jun;27(6):1811-22
pubmed: 26567244
J Am Soc Nephrol. 2003 Jun;14 Suppl 1:S22-6
pubmed: 12761234
Nephron. 2018;138(1):71-87
pubmed: 28965116
Lancet. 2003 Aug 23;362(9384):629-39
pubmed: 12944064
Front Immunol. 2019 Jul 16;10:1653
pubmed: 31379849
Arthritis Res Ther. 2018 Oct 3;20(1):222
pubmed: 30285841
Eur J Immunol. 1994 May;24(5):1218-22
pubmed: 8181532
J Clin Med. 2018 Sep 09;7(9):
pubmed: 30205613
Immunity. 2010 Jan 29;32(1):129-40
pubmed: 20079667
Pediatr Nephrol. 2009 Jul;24(7):1321-8
pubmed: 19421786
Nat Rev Immunol. 2015 Mar;15(3):160-71
pubmed: 25698678
Pediatr Nephrol. 2010 Jun;25(6):1109-15
pubmed: 20238230
J Immunol. 1990 Oct 15;145(8):2390-6
pubmed: 1976692
Am J Transplant. 2019 Feb;19(2):368-380
pubmed: 30085394
J Immunol. 2014 May 1;192(9):4242-53
pubmed: 24696233
Immunity. 2015 Apr 21;42(4):607-12
pubmed: 25902480
Immunobiology. 2017 Apr;222(4):620-630
pubmed: 27986304
Inflammopharmacology. 2018 Oct;26(5):1331-1338
pubmed: 29159714
Neurol Ther. 2018 Dec;7(2):373-383
pubmed: 29881979
Kidney Int. 2017 Jul;92(1):227-237
pubmed: 28318628
J Immunol. 1986 Jan;136(1):83-92
pubmed: 3484392
Eur J Pediatr. 2016 May;175(5):685-93
pubmed: 26833050
J Am Soc Nephrol. 2014 Apr;25(4):850-63
pubmed: 24480824
J Clin Invest. 2020 Jan 2;130(1):480-490
pubmed: 31815738
J Am Soc Nephrol. 2015 Sep;26(9):2259-66
pubmed: 25592855
N Engl J Med. 1996 Apr 4;334(14):878-83
pubmed: 8596570
Kidney Int. 2019 Aug;96(2):436-449
pubmed: 31040060
Lancet. 2014 Oct 4;384(9950):1273-81
pubmed: 24965823
Cell. 2017 May 4;169(4):750-765.e17
pubmed: 28475900
Cell. 2015 Jul 2;162(1):184-97
pubmed: 26095251
BMJ Open. 2017 Mar 17;7(3):e013319
pubmed: 28314744
Pediatr Nephrol. 2019 Jan;34(1):177-181
pubmed: 30267238
Pediatr Int. 2017 May;59(5):643-646
pubmed: 28544686
Science. 2013 Sep 13;341(6151):1205-11
pubmed: 24031013
N Engl J Med. 2009 Nov 26;361(22):2143-52
pubmed: 19940299
Immunol Res. 2000;21(1):23-30
pubmed: 10803880
J Immunol Methods. 2004 Mar;286(1-2):111-22
pubmed: 15087226
Blood. 2004 Sep 15;104(6):1793-800
pubmed: 15172969
N Engl J Med. 2005 Dec 1;353(22):2342-51
pubmed: 16319383
Nephrol Dial Transplant. 2014 Nov;29(11):2084-91
pubmed: 24920841
Autoimmun Rev. 2005 Nov;4(8):549-54
pubmed: 16214094
Lancet. 1974 Sep 7;2(7880):556-60
pubmed: 4140273
Pediatr Nephrol. 2007 Feb;22(2):232-6
pubmed: 17043884
J Pediatr. 1979 Aug;95(2):239-43
pubmed: 109598
Trends Immunol. 2008 Jan;29(1):34-40
pubmed: 18289504
Immunity. 1995 Mar;2(3):239-48
pubmed: 7535180
Am J Transplant. 2016 Feb;16(2):672-8
pubmed: 26552037
J Autoimmun. 2018 Mar;88:91-102
pubmed: 29056249
Arthritis Rheum. 2006 Feb;54(2):613-20
pubmed: 16447239
J Am Soc Nephrol. 1997 May;8(5):769-76
pubmed: 9176846
J Allergy Clin Immunol. 2013 Apr;131(4):1204-12
pubmed: 23453135
Nephrol Dial Transplant. 2012 Mar;27(3):1083-9
pubmed: 21810762
Blood. 2005 Apr 15;105(8):3042-50
pubmed: 15613544
Vaccine. 2009 Dec 10;28(1):179-86
pubmed: 19799844